Stenotrophomonas maltophilia: Changing spectrum of a serious bacterial pathogen in patients with cancer

Clinical Infectious Diseases

Volumn 45, Issue 12, 2007, Pages 1602-1609

  Safdar, Amar ^a   Rolston, Kenneth V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; MINOCYCLINE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; TIMENTIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATION; BILIARY TRACT INFECTION; CATHETER INFECTION; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; ENDOCARDITIS; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; INFECTION RISK; MEDICAL DOCUMENTATION; MEMBRANE PERMEABILITY; MENINGITIS; MULTIDRUG RESISTANCE; NEOPLASM; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PYOMYOSITIS; REVIEW; SKIN INFECTION; SKIN STRUCTURE; STENOTROPHOMONAS MALTOPHILIA; URINARY TRACT INFECTION; DISEASE PREDISPOSITION; DRUG EFFECT; GRAM NEGATIVE INFECTION; HEALTH SURVEY; IMMUNE DEFICIENCY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; RISK FACTOR;

ANTI-BACTERIAL AGENTS; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; NEOPLASMS; POPULATION SURVEILLANCE; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA;

EID: 40449108309     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522998     Document Type: Review

References (87)

1. Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 2001; 17:531-70.
2. Safdar A, Rodriguez GH, Balakrishnan M, Tarrand JJ, Rolston KVI. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis 2006; 25:522-6.
3. Rolston KVI, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH. The spectrum of gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against gram-positive bacteria isolated from cancer patient. Int J Infect Dis 2006; 10:223-30.
4. Rolston KVI, Kontoyiannis DP, Yadegarynia D, Raad I. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis 2005; 51:215-8.
5. Aisenberg G, Rolston KV, Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 2004; 101:2134-40.
6. Morrison AJ, Hoffman KF, Weizel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24:52-5.
7. Whimbey E, Kiehn TE, Brannon P, Benezra D, Armstrong D. Clinical significance of colony counts in immunocompromised patients with Staphylococcus aureus bacteremia. J Infect Dis 1987; 155:1328-30.
8. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-9.
9. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35:228-35.
10. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999; 11:28-33.
11. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and nonaeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine 1990; 69:296-306.
12. Martino R, Martinez C, Pericas R, et al. Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematologic neoplasias and solid tumors. Eur J Clin Microbiol Infect Dis 1996; 15: 610-5.
13. Labarca JA, Leber AL, Kern VL, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogeneic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis 2000; 30: 195-7.
14. Apisarnthanarak A, Mayfield JL, Garison T, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 2003; 24:269-74.
15. Vartivarian SE, Papadakis KA, Anaissie EJ. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection: a disease that is usually severe and complicated. Arch Intern Med 1996; 156:433-5.
16. Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Clin Infect Dis 1995; 21:1032-4.
17. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis 2007; 26:13-20.
18. Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 1999; 45:325-34.
19. Rolston KVI, Kontoyiannis DP, Raad II, LeBlanc BJ, Streeter HL, Ho DH. Susceptibility surveillance among gram-negative bacilli at a comprehensive cancer center [abstract A-004]. In: Program and abstracts of the 103rd General Meeting of American Society of Microbiology (Washington, DC). Washington, DC: American Society of Microbiology, 2003:1.
20. Apisarnthanarak A, Fraser VJ, Dunne WM, et al. Stenotrophomonas maltophilia intestinal colonization in hospital oncology patients with diarrhea. Clin Infect Dis 2003; 37:1131-5.
21. Villarino MF, Stevens LE, Schable B, et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992; 13:201-6.
22. Boktour M, Hanna H, Ansari S, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 2006; 106:1967-73.
23. Bodey GP, Ho DH, Elting L. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer hospital. Am J Med 1988; 85:49-51.
24. Rolston KVI, Elting L, Waguespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 1996; 42:348-53.
25. Huang WT, Chen TY, Su WC, Yen CJ, Tsao CJ. Implantable venous port-related infections in cancer patients. Support Care Cancer 2004; 12:197-201.
26. Lai CH, Wong WW, Chin C, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteremia and associated relapsing bacteremia in haematology and oncology patients. Clin Microbiol Infect 2006; 12:986-91.
27. Hanna H, Afif C, Alakech B, et al. Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 2004; 25: 646-9.
28. Cherif H, Kronvall G, Bjorkholm M, Kalin M. Bacteremia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 2003; 4:420-5.
29. Lai CH, Chi CY, Chen HP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004; 37:350-8.
30. Teo WY, Chan MY, Lam CM, Chong CY. Skin manifestation of Stenotrophomonas maltophilia infection - a case report and review article. Ann Acad Med Singapore 2006; 35:897-900.
31. Sefcick A, Tait RC, Wood B. Stenotrophomonas maltophilia: an increasing problem in patients with acute leukemia. Leuk Lymphoma 1999; 35:207-11.
32. Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia meningitis: report of two cases and review of the literature. J Neurosurg 1997; 87:106-8.
33. Wu PS, Lu CY, Chang LY, et al. Stenotrophomonas maltophilia bacteremia in pediatric patients - a 10-year analysis. J Microbiol Immunol Infect 2006; 39:144-9.
34. Martino R, Gomez L, Pericas R, et al. Bacteraemia caused by nonglucose-fermenting gram-negative bacilli and Aeromonas species in patients with haematological malignancies and solid tumours. Eur J Clin Microbiol Infect Dis 2000; 19:320-3.
35. Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000; 31:705-11.
36. Lechner A, Hindler JF, Nelson SF. Biclonal bacteremia due to Stenotrophomonas maltophilia in a cancer patient. Eur J Clin Microbiol Infect Dis 2001; 20:673-5.
37. Miyairi I, Franklin JA, Andreansky M, Knapp KM, Hayden RT. Acute necrotizing ulcerative gingivitis and bacteremia caused by Stenotrophomonas maltophilia in an immunocompromised host. Pediatr Infect Dis J 2005; 24:181-3.
38. Han XY, Kamana M, Rolston KV. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 2006; 44:160-5.
39. Khan I, Mehta NJ. Stenotrophomonas maltophilia endocarditis: a systemic review. Angiology 2002; 53:49-55.
40. Crum NF, Utz GC, Wallace MR. Stenotrophomonas maltophilia endocarditis. Scand J Infect Dis 2002; 34:925-7.
41. Yusuf SW, Ali SS, Swafford J, et al. Culture-positive and culture-negative endocarditis in patients with cancer: a retrospective observational study, 1994-2004. Medicine (Baltimore) 2006; 85:86-94.
42. Tsai SH, Chao TY, Chou TD, Dai MS. Stenotrophomonas maltophilia septicemia with pyomyositis in a chemotherapy-treated patient. Ann Hematol 2003; 82:452-4.
43. Fujita J, Yamadori I, Xu G, et al. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir Med 1996; 90:35-8.
44. Vartivarian SE, Anaissie EJ, Kiwan EN, Papadakis KA. The clinical spectrum of Stenotrophomonas (Xanthomonas) maltophilia respiratory infections. Semin Respir Crit Care Med 2000; 21:349-55.
45. Safdar A, Gonzalez O, Girgawy E. Changing spectrum of post-viral pneumonia in hospitalized patients with cancer [abstract 64]. In: Program and abstracts of the 13th International Symposium on Infections in the Immunocompromised Host. International Immunocompromised Host Society. [Granada, Spain June 27-30, 2004.] Intl J Infect Dis 2004; 8(Suppl 1):S36.
46. Rousseau A, Morcos M, Amrouche L, et al. Lethal pulmonary hemorrhage caused by a fulminant Stenotrophomonas maltophilia respiratory infection in an acute myeloid leukemia patient. Leuk Lymphoma 2004; 45:1293-6.
47. McGowan JE. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006; 119(Suppl 1): S29-36.
48. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteremia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002; 45:47-53.
49. Tsai WP, Chen CL, Ko WC, Pan SC. Stenotrophomonas maltophilia bacteremia in burn patients. Burns 2006; 32:155-8.
50. Khardori N, Reuben A, Rosenbaum B, Rolston K, Bodey GP. In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother 1990; 34:1609-10.
51. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994; 38:624-7.
52. Nicodemo AC, Garcia Paez JI. Antimicrobial therapy of Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007; 26: 229-37.
53. Barbolla R, Catalano M, Orman BE, et al. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 2004; 48:666-9.
54. Lecso-Bornet M, Pierre J, Sarkis-Karam D, Bergogne-Gerezin E. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selection in vitro. Antimicrob Agents Chemother 1992; 36:669-71.
55. Jones RN, Pfaller MA, Marshall SA, Hollis RJ, Wilke WW. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagn Microbiol Infect Dis 1997; 29: 187-92.
56. Traub WH, Leonhard B, Bauer D. Stenotrophomonas (Xanthomonas) maltophilia: in vitro susceptibility to selected antimicrobial drugs, single and combined, with and without defibrinated human blood. Chemotherapy 1998; 44:293-304.
57. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 2001; 41:71-8.
58. Crowder MW, Walsh TR, Banovic L, Pettit M, Spencer J. Overexpression, purification and characterization of the cloned metallo-betalactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1998; 42:921-6.
59. Walsh TR, MacGowen AP, Bennett PM. Sequence analysis and enzyme kinetics of the L2 serine β-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41:1460-4.
60. Avison MB, Higgins CS, Von Heldreich CJ, Bennet PM, Walsh TR. Plasmid location ad molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45:413-9.
61. Alonso A, Martinez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000; 44:3079-86.
62. Lecso-Bornet M, Pierre J, Sarkis-Karam D, Bergogne-Gerezin E. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane protein in resistant mutants selection in vitro. Antimicrob Agents Chemother 1992; 36:669-71.
63. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005; 52:187-93.
64. Noskin GA. Tigecycline: a new glycycline for treatment of serious infections. Clin Infect Dis 2005; 41:S303-14.
65. Tan TY, Ng SY. The in-vitro activity of colistin in gram-negative bacteria. Singapore Med J 2006; 47:621-4.
66. Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 1995; 39: 2220-3.
67. Carroll KC, Cohen S, Nelson R, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 1998; 32;229-35.
68. Traub WH, Leonhard B, Bauer D. Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. Chemotherapy 1998; 44:164-73.
69. Yilmaz M, Celik AF, Mert A. Successful treated nosocomial Stenotrophomonas maltophilia bacteremia following desensitization to trimethoprim-sulfamethoxazole. J Infect Chemother 2007; 13:122-3.
70. Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007; 109:2615-22.
71. Venditti M, Monaco M, Micozzi A, Tarasi A, Friedrich A, Martino P. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies. Clin Microbiol Infect 2001; 7:37-39.
72. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile neutropenia. Clin Infect Dis 1999; 29:495-502.
73. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119(Suppl 2):S397-404.
74. Bustamante CI, Wharton RC,Wade JC. In vitro activity of ciprofloxacin in combination to ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990; 34:1814-15.
75. Pendland SL, Messick CR, Jung R. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Inect Dis 2002; 42:75-8.
76. Oie S, Uematsu T, Sawa A, et al. In vitro effects of combination of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003; 52:911-4.
77. Sader HS, Rhomberg PR, Jones RN. In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. J Chemother 2005; 17:622-7.
78. Ghannam DE, Rodriguez GH, Adachi J, et al. Efficacy of inhaled (Ih)-aminoglycosides (AG) and colistin (CL) in cancer patients with ventilator-associated pneumonia (VAP) during 2000-2005 [abstract K-288]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006: 311.
79. Muratani T, Yokota E, Nakane T, Inoue E, Mitsuhashi S. In vitro evaluation of the four β-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam and tazobactam. J Antimicrob Chemother 1993; 32: 421-9.
80. Georgopapadakou NH. β-Lactamase inhibitors: evolving compounds for evolving resistance targets. Expert Opin Investig Drugs 2004; 13: 1307-18.
81. Piers KL, Hancock REW. The interaction of a recombinant cecropin/ melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa. Mol Microbiol 1994; 12:951-8.
82. Zuercher AW, Imboden MA, Jampen S, et al. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol 2006; 143:132-8.
83. Bertot GM, Restelli MA, Galanternik L, Aranibar Urey RC, Valvano MA, Grinstein S. Nasal immunization with Burkholderia multivorns outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia. Infect Immun 2007; 75: 2740-52.
84. Maisetta G, Batoni G, Esin S, et al. In vitro bactericidal activity of human β-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob Agents Chemother 2006; 50:806-9.
85. Waters VJ, Gomez MI, Soong G, Amin S, Ernst RK, Prince A. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun 2007; 75:1698-1703.
86. Nseir S, Di Pompeo C, Diarra M, et al. Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study. Crit Care Med 2007; 35:1318-23.
87. Khardori N, Elting L, Wong E, Schable B, Bodey GP. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990; 12:997-1003.